CytomX Therapeutics Reports Full Year 2022 Financial Results and Provides Business Update

March 27, 2023

https://www.globenewswire.com/news-release/2023/03/27/2635245/37704/en/CytomX-Therapeutics-Reports-Full-Year-2022-Financial-Results-and-Provides-Business-Update.html

– Internal focus on next generation therapeutic pipeline including ongoing Phase 1 for CX-904 (EGFRxCD3) and anticipated IND filings for CX-2051 (EpCAM-directed ADC) and CX-801 (Interferon alpha-2b) in the second half of 2023 –

Read more at globenewswire.com

Related news for (CTMX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.